NCT05498896: BARBICAN

Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC

Active, enrolled Phase 2 Last updated 10 March 2025

What this trial tests

Phase 2 trial testing Atezolizumab in Triple Negative Breast Cancer in 146 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

19 December 2018

Primary endpoint
29 January 2021

30 January 2026

Quick facts

Lead sponsor	Queen Mary University of London
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	146
Start date	19 December 2018
Primary completion	29 January 2021
Estimated completion	30 January 2026
Sites	1 location across United Kingdom

Drugs / interventions tested

• Atezolizumab (atezolizumab) — full drug profile →
• Ipatasertib
• Paclitaxel — full drug profile →
• Doxorubicin (doxorubicin) — full drug profile →
• Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

• Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →

Sponsor

Queen Mary University of London

Who can join

18 and older, female only, with Triple Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

International, randomised, open label, neo-adjuvant phase II trial in women with newly diagnosed, non-metastatic, high-risk (node positive and/or tumour size ≥ 2cm), triple negative breast cancer. The study aims to evaluate the effects of adding ipatasertib to chemotherapy and atezolizumab in patients with and without PI3CA/AKT1/PTEN genetic alterations.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy.
   Sirico M, D'Angelo A, Gianni C, Casadei C, et al · · 2023 · cited 76× · PMID 36765661 · DOI 10.3390/cancers15030703
2. Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome.
   Li L, Zhang F, Liu Z, Fan Z. · · 2023 · cited 73× · PMID 36612317 · DOI 10.3390/cancers15010321
3. Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer.
   Yang T, Li W, Huang T, Zhou J. · · 2023 · cited 24× · PMID 36983708 · DOI 10.3390/jpm13030526
4. Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment.
   Yang Y, Li H, Yang W, Shi Y. · · 2024 · cited 11× · PMID 39430759 · DOI 10.3389/fimmu.2024.1441667
5. Signaling pathway dysregulation in breast cancer.
   Ryspayeva D, Seyhan AA, MacDonald WJ, Purcell C, et al · · 2025 · cited 9× · PMID 40080721 · DOI 10.18632/oncotarget.28701
6. Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects.
   Khadela A, Soni S, Megha K, Shah AC, et al · · 2022 · cited 6× · PMID 36520261 · DOI 10.1007/s12032-022-01922-6
7. Computer-Aided Identification of Kinase-Targeted Small Molecules for Cancer: A Review on AKT Protein.
   Primavera E, Palazzotti D, Barreca ML, Astolfi A. · · 2023 · cited 3× · PMID 37513905 · DOI 10.3390/ph16070993
8. Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention.
   Lei H, Fu J, Gu W, Qiao H, et al · · 2026 · PMID 41510186 · DOI 10.1002/mco2.70560